The role for interleukin-12 therapy of cutaneous T cell lymphoma

Alain H. Rook, Mohamed H. Zaki, Maria Wysocka, Gary S. Wood, Madeleine Duvic, Louise C. Showe, Francine Foss, Michael Shapiro, Timothy M. Kuzel, Elise A. Olsen, Eric C. Vonderheid, Robert Laliberte, Matthew L. Sherman

Research output: Contribution to journalArticlepeer-review


Recent phase I and phase II trials using recombinant human interleukin-12 (rhIL-12) for cutaneous T cell lymphoma (CTCL) have been completed. Observations on 32 evaluable patients revealed an overall response rate approaching 50 percent. Biopsy of regressing lesions revealed an increase in numbers of CD8+ and/or TIA-1+ T cells. These results suggest that rhIL-12 may induce lesion regression by augmenting antitumor cytotoxic T cell responses. Future trials will be focused on strategies for further immune enhancement by the concomitant use of additional immune augmenting cytokines with rhIL-12.

Original languageEnglish (US)
Pages (from-to)177-184
Number of pages8
JournalAnnals of the New York Academy of Sciences
StatePublished - 2001
Externally publishedYes


  • Interferon-γ
  • Interleukin-2
  • Recombinant human interleukin-12

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'The role for interleukin-12 therapy of cutaneous T cell lymphoma'. Together they form a unique fingerprint.

Cite this